Boston Scientific Corporation (BSX) : Quantitative Investment Management scooped up 233,800 additional shares in Boston Scientific Corporation during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 2, 2016. The investment management firm now holds a total of 515,400 shares of Boston Scientific Corporation which is valued at $12,287,136.Boston Scientific Corporation makes up approximately 0.55% of Quantitative Investment Management’s portfolio.
Other Hedge Funds, Including , Deroy Devereaux Private Investment Counsel Inc reduced its stake in BSX by selling 165,860 shares or 23.74% in the most recent quarter. The Hedge Fund company now holds 532,725 shares of BSX which is valued at $12,588,292. Boston Scientific Corporation makes up approx 1.62% of Deroy Devereaux Private Investment Counsel Inc’s portfolio.
Boston Scientific Corporation closed down -0.26 points or -1.08% at $23.88 with 69,59,412 shares getting traded on Monday. Post opening the session at $24.16, the shares hit an intraday low of $23.82 and an intraday high of $24.18 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.
On the company’s financial health, Boston Scientific Corporation reported $0.27 EPS for the quarter, based on the information available during the earnings call on Jul 28, 2016. Analyst had a consensus estimate of $0.27. The company had revenue of $2126.00 million for the quarter, compared to analysts expectations of $2044.88 million. The company’s revenue was up 15.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.22 EPS.
Many Wall Street Analysts have commented on Boston Scientific Corporation. Company shares were Reiterated by Wedbush on Jul 29, 2016 to “Neutral”, Firm has raised the Price Target to $ 25 from a previous price target of $23 .Company shares were Reiterated by Needham on Jul 29, 2016 to “Buy”, Firm has raised the Price Target to $ 28 from a previous price target of $26 .Company shares were Reiterated by The Benchmark Company on Jul 28, 2016 to “Buy”, Firm has raised the Price Target to $ 31 from a previous price target of $25 .
Boston Scientific Corporation develops manufactures and markets medical devices. The Company offers its products by seven core businesses: Interventional Cardiology which includes Drug-Eluting Coronary Stent Systems Intravascular Imaging devised and Coronary Technology products such as guide wires guide catheters and balloon catheters among others; Peripheral Interventions (PI) which include stents balloon catheters wires peripheral embolization devices and vena cava filters; Cardiac Rhythm Management (CRM) which include implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities; Electrophysiology (EP) which include steerable RF ablation catheters intracardiac ultrasound catheters diagnostic catheters delivery sheaths and other accessories; Endoscopy which includes Spyglass System WallFlex Colonic Stents Resolution Clip and Expect Aspiration Needle among others; Urology and Womens Health and Neuromodulation.